Purine import into malaria parasites as a target for antimalarial drug development

被引:30
|
作者
Frame, I. J. [1 ]
Deniskin, Roman [1 ]
Arora, Avish [1 ]
Akabas, Myles H. [1 ,2 ,3 ]
机构
[1] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
来源
MALARIA: ADVANCES IN PATHOPHYSIOLOGY, BIOLOGY, AND DRUG DEVELOPMENT | 2015年 / 1342卷
关键词
purines; nucleoside transporter; malaria; drug development; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; PLASMODIUM-FALCIPARUM; HUMAN-ERYTHROCYTES; FUNCTIONAL-CHARACTERIZATION; NUCLEOBASE TRANSPORT; PLASMA-MEMBRANE; S-6-(4-NITROBENZYL)-MERCAPTOPURINE RIBOSIDE; SACCHAROMYCES-CEREVISIAE; CYTOKININ BIOSYNTHESIS; LEISHMANIA-DONOVANI;
D O I
10.1111/nyas.12568
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Infection with Plasmodium species parasites causes malaria. Plasmodium parasites are purine auxotrophs. In all life cycle stages, they require purines for RNA and DNA synthesis and other cellular metabolic processes. Purines are imported from the host erythrocyte by equilibrative nucleoside transporters (ENTs). They are processed via purine salvage pathway enzymes to form the required purine nucleotides. The Plasmodium falciparum genome encodes four putative ENTs (PfENT1-4). Genetic, biochemical, and physiologic evidence suggest that PfENT1 is the primary purine transporter supplying the purine salvage pathway. Protein mass spectrometry shows that PfENT1 is expressed in all parasite stages. PfENT1 knockout parasites are not viable in culture at purine concentrations found in human blood (<10 mu M). Thus, PfENT1 is a potential target for novel antimalarial drugs, but no PfENT1 inhibitors have been identified to test the hypothesis. Identifying inhibitors of PfENT1 is an essential step to validate PfENT1 as a potential antimalarial drug target.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 50 条
  • [41] The development of and perspectives for genetic engineering of malaria parasites
    Waters, AP
    Janse, CJ
    PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, 1999, : 453 - 459
  • [42] Hybrid Gold(I) NHC-Artemether Complexes to Target Falciparum Malaria Parasites
    Ouji, Manel
    Barnoin, Guillaume
    Fernandez Alvarez, Alvaro
    Augereau, Jean-Michel
    Hemmert, Catherine
    Benoit-Vical, Francoise
    Gornitzka, Heinz
    MOLECULES, 2020, 25 (12):
  • [43] Helicases -: feasible antimalarial drug target for Plasmodium falciparum
    Tuteja, Renu
    FEBS JOURNAL, 2007, 274 (18) : 4699 - 4704
  • [44] Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development
    Abd-Rahman, Azrin N.
    Zaloumis, Sophie
    McCarthy, James S.
    Simpson, Julie A.
    Commons, Robert J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (02)
  • [45] Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria
    Hoelz, Lucas V. B.
    Calil, Felipe A.
    Nonato, Maria C.
    Pinheiro, Luiz C. S.
    Boechat, Nubia
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (15) : 1853 - 1874
  • [46] Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis
    Baragana, Beatriz
    Forte, Barbara
    Choi, Ryan
    Hewitt, Stephen Nakazawa
    Bueren-Calabuig, Juan A.
    Pisco, Joao Pedro
    Peet, Caroline
    Dranow, David M.
    Robinson, David A.
    Jansen, Chimed
    Norcross, Neil R.
    Vinayak, Sumiti
    Anderson, Mark
    Brooks, Carrie F.
    Cooper, Caitlin A.
    Damerow, Sebastian
    Delves, Michael
    Dowers, Karen
    Duffy, James
    Edwards, Thomas E.
    Hallyburton, Irene
    Horst, BenjaminG.
    Hulverson, Matthew A.
    Ferguson, Liam
    Belen Jimenez-Diaz, Maria
    Jumani, Rajiv S.
    Lorimer, Donald D.
    Love, Melissa S.
    Maher, Steven
    Matthews, Holly
    McNamara, Casew.
    Miller, Peter
    O'Neill, Sandra
    Ojo, Kayode K.
    Osuna-Cabello, Maria
    Pinto, Erika
    Post, John
    Riley, Jennifer
    Rottmann, Matthias
    Sanz, Laura M.
    Scullion, Paul
    Sharma, Arvind
    Shepherd, Sharon M.
    Shishikura, Yoko
    Simeons, Frederick R. C.
    Stebbins, Erin E.
    Stojanovski, Laste
    Straschil, Ursula
    Tamaki, Fabio K.
    Tamjar, Jevgenia
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (14) : 7015 - 7020
  • [47] Effect of Drug Pressure on Promoting the Emergence of Antimalarial-Resistant Parasites among Pregnant Women in Ghana
    Tornyigah, Bernard
    Coppee, Romain
    Houze, Pascal
    Kusi, Kwadwo A.
    Adu, Bright
    Quakyi, Isabella
    Coleman, Nathaniel
    Mama, Atikatou
    Deloron, Philippe
    Anang, Abraham K.
    Clain, Jerome
    Tahar, Rachida
    Ofori, Michael F.
    Ndam, Nicaise Tuikue
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
  • [48] Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management
    Segovia, Xyonane
    Srivastava, Bhavya
    Serrato-Arroyo, Sergio
    Guerrero, Ashley
    Huijben, Silvie
    MALARIA JOURNAL, 2025, 24 (01)
  • [49] DNA damage regulation and its role in drug-related phenotypes in the malaria parasites
    Gupta, Devendra Kumar
    Patra, Alok Tanala
    Zhu, Lei
    Gupta, Archana Patkar
    Bozdech, Zbynek
    SCIENTIFIC REPORTS, 2016, 6
  • [50] Insight into molecular diagnosis for antimalarial drug resistance of Plasmodium falciparum parasites: A review
    Zhong, Ao
    Zhang, Han
    Li, Jian
    ACTA TROPICA, 2023, 241